« Back to Record
Citation APA

Rossignol, P., Zannad, F., Massy, Z. A., Azizi, M., Chorfa, F., Coadic, J., Ferreira, J. P., Saraiva, F., Mottier, D., Guillemin, F., Ngueyon Sime, W., Bouali, S., Rossignol, B., Nortier, J., Simon, I., Robino, C., Davin, M., Bataille, P., Chantrel, F., Castin, N., Esnault, V., Kazes, I., Hannedouche, T., Kamar, N., Achard, J. M., Fenerol, C., Achard-Hottelart, C., Dimitrov, Y., Girerd, N., Maucourt-Boulch, D., & Frimat, L. (2025). Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet, 406(10504), 705-718. doi:10.1093/ced/llae373


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/396343

Rossignol, P., Zannad, F., Massy, Z. A., Azizi, M., Chorfa, F., Coadic, J., Ferreira, J. P., Saraiva, F., Mottier, D., Guillemin, F., Ngueyon Sime, W., Bouali, S., Rossignol, B., Nortier, J., Simon, I., Robino, C., Davin, M., Bataille, P., Chantrel, F., Castin, N., Esnault, V., Kazes, I., Hannedouche, T., Kamar, N., Achard, J. M., Fenerol, C., Achard-Hottelart, C., Dimitrov, Y., Girerd, N., Maucourt-Boulch, D., & Frimat, L. (2025). Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet, 406(10504), 705-718. doi:10.1093/ced/llae373